GILLIS JONATHAN
Known title: CAAO and PAOCIK: 0001709954
Associated companies
Transaction History
| MPLT | ▲ Buy | Grant | 6,020 | $0 | 8/17/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 2,222 | $0 | 8/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 16,969 | $638K | 7/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 900 | $34K | 7/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 600 | $22K | 7/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 6,979 | $256K | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 1,476 | $55K | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 5,356 | $194K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 4,699 | $174K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 17,235 | $523K | 4/28/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 700 | $22K | 4/28/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 7,914 | $229K | 4/27/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 29,623 | $877K | 4/27/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 14,363 | $437K | 4/27/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 3,590 | $96K | 4/15/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 6,020 | $0 | 2/5/2026 | View on chart |
| MPLT | ▼ Sell | Tax Withholding | 22,050 | $396K | 1/27/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 30,565 | $0 | 10/27/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.